Alprostadil (Caverject/MUSE) Pediatric Safety: What Clinicians Need to Know for Children Under 12

What Is Alprostadil and Why Does Pediatric Context Matter?

Alprostadil is synthetic prostaglandin E1 (PGE1). It relaxes smooth muscle in vascular walls and the ductus arteriosus, and it is this property that makes it medically indispensable in neonatal cardiology while also forming the pharmacological basis of its adult erectile dysfunction applications. The critical starting point for any clinician or caregiver searching for pediatric safety data is recognizing that the brand names Caverject and MUSE represent intracavernosal and intraurethral formulations designed exclusively for adult males with erectile dysfunction. Linet et al. (NEJM 1996, N=296) demonstrated approximately 70% response rates with intracavernosal alprostadil in men with refractory ED, establishing its adult role solidly [1]. No equivalent pediatric ED indication exists, because the condition itself does not present in children under 12.

The pediatric safety story of alprostadil is therefore almost entirely about intravenous prostaglandin E1 in neonates and young infants with ductus-dependent congenital heart defects. This population may include newborns with transposition of the great arteries, pulmonary atresia, tricuspid atresia, critical coarctation of the aorta, hypoplastic left heart syndrome, and related lesions where survival depends on keeping the ductus arteriosus open until surgical or catheter-based correction can proceed. Understanding this distinction prevents both clinical errors and parental confusion.

Alprostadil's mechanism in the ductus is dose-dependent smooth muscle relaxation mediated through EP2 and EP4 prostaglandin receptors, which reduce cyclic AMP degradation and sustain ductal patency [2]. In adult penile tissue, the same receptor pathways relax cavernosal smooth muscle to enable erection. The molecule is identical; the delivery route, dose, clinical population, and risk profile are entirely different.

FDA Labeling for Alprostadil in Pediatric Patients

The FDA has not approved Caverject (intracavernosal alprostadil, Pfizer) or MUSE (alprostadil urethral suppository, Meda Pharmaceuticals) for any use in patients under 18, and certainly not in children under 12. The prescribing information for Caverject states explicitly that the drug is indicated for erectile dysfunction in adult males and provides no pediatric dosing section, because no appropriate indication exists [3].

Intravenous alprostadil for neonatal use operates under different regulatory history. Prostin VR Pediatric (alprostadil sterile solution, Pfizer) carries FDA labeling specifically for neonates with ductus-dependent congenital heart disease. The approved starting dose in that label is 0.05 to 0.1 mcg/kg/min by continuous intravenous infusion, with the option to reduce to 0.01 to 0.05 mcg/kg/min once a satisfactory response (increased PO2 or increased systemic blood pressure) is achieved [4]. The labeling directly addresses pediatric use with weight-based dosing, something completely absent from the Caverject or MUSE documents.

The American Academy of Pediatrics and the American Heart Association both include prostaglandin E1 infusion as a Class I recommendation in neonatal resuscitation guidelines for suspected ductus-dependent lesions when echocardiography is not immediately available [5]. This recommendation underscores how standard-of-care the IV formulation has become in pediatric critical care, while the adult formulations remain entirely outside the pediatric scope.

A useful three-category framework for clinicians fielding alprostadil questions in young patients:

Category A. Neonates and infants (<6 months) with ductus-dependent CHD. IV alprostadil (Prostin VR Pediatric) is indicated and evidence-based. Dose titration, apnea monitoring, and specialist oversight are mandatory.

Category B. Children 6 months to 12 years with non-cardiac off-label queries. No established clinical indication for any alprostadil formulation exists. Requests should prompt investigation of the underlying concern rather than prescribing.

Category C. Accidental exposure to adult formulations (Caverject, MUSE). Treat as a poisoning event. Contact Poison Control (1-800-222-1222 in the US) and assess for hypotension, vasodilation, and respiratory compromise.

Dosing Principles for Neonatal IV Alprostadil

Neonatal dosing of IV alprostadil follows weight-based protocols that bear no resemblance to adult ED dosing. Caverject is supplied as 10 to 40 mcg powder for reconstitution and injected in microgram quantities directly into penile tissue. Prostin VR Pediatric is diluted for continuous IV infusion at nanogram-per-kilogram-per-minute precision.

The standard initiation rate of 0.05 to 0.1 mcg/kg/min is typically prepared by adding 500 mcg of alprostadil to 250 mL of 0.9% sodium chloride or 5% dextrose, yielding a 2 mcg/mL solution. For a 3 kg neonate at 0.05 mcg/kg/min, the infusion rate is 0.075 mL/min or 4.5 mL/hour. Doses above 0.4 mcg/kg/min have not shown additional benefit and substantially increase adverse effect risk [4].

Once ductal patency is confirmed (typically by increased oxygen saturation, improved peripheral perfusion, or direct echocardiographic visualization), the infusion is weaned to the lowest effective dose. Most centers target 0.01 to 0.025 mcg/kg/min for maintenance. Duration is usually measured in days to weeks, bridging the neonate to surgical repair or palliative catheter intervention.

Growth and developmental monitoring becomes relevant when infusions extend beyond one to two weeks. Cortical hyperostosis (periosteal new bone formation) has been documented in neonates receiving prolonged PGE1 infusions, affecting the long bones, ribs, and clavicles [6]. The condition is generally reversible after discontinuation, but radiographic surveillance is warranted for any infant on alprostadil for more than 14 days. Cardiology teams routinely schedule plain radiographs of the long bones at that threshold.

Adverse Effects in Pediatric Patients: Frequency and Severity

The adverse effect profile of IV alprostadil in neonates differs substantially from the local effects seen with adult intracavernosal or intraurethral use. Adults using Caverject primarily experience penile pain (in roughly 37% of injections per the Linet 1996 trial) and, less commonly, prolonged erection [1]. Neonates receiving IV prostaglandin E1 face systemic cardiovascular and respiratory consequences.

Apnea is the most clinically serious adverse effect. The Prostin VR Pediatric prescribing label reports apnea in approximately 10 to 12% of neonates, with highest incidence in those weighing less than 2 kg at birth [4]. Apnea may occur within the first hour of infusion or at any point during treatment. All neonates receiving IV alprostadil must be monitored in a setting capable of respiratory support, with intubation equipment immediately available.

Fever occurs in up to 14% of neonates on PGE1 infusion. It is dose-related and thought to reflect prostaglandin's role in thermoregulation via hypothalamic EP3 receptors. Fever in a neonate receiving alprostadil should be assessed for infectious sources, but clinicians should also consider the drug itself as a contributing factor before initiating broad-spectrum antibiotics without other clinical grounds [4].

Systemic hypotension appears in roughly 4% of treated neonates. Because many ductus-dependent lesions already compromise systemic perfusion, close blood pressure monitoring with arterial line placement is standard practice in tertiary neonatal intensive care units. Hypotension responds to dose reduction and volume support in most cases.

Bradycardia occurs in approximately 7% of patients. The mechanism appears to involve PGE1-mediated slowing of sinoatrial node firing. Continuous cardiac monitoring detects this early, and dose reduction typically reverses it within minutes.

Seizure-like activity has been reported rarely, though distinguishing drug-induced jitteriness from true seizure in neonates requires electroencephalographic correlation [4].

Diarrhea and gastric outlet obstruction are reported with prolonged use. Gastric antral hyperplasia sufficient to cause outlet obstruction has been described in case reports of neonates on infusions lasting more than two weeks, though the frequency is low enough that it does not appear in the prescribing label's percentage-based tables [6].

Regarding the adult formulations specifically: if a child under 12 accidentally contacts or is administered Caverject or MUSE, the primary concerns are systemic hypotension from absorbed prostaglandin E1 and local tissue injury at the site of contact. The FDA MedWatch database has received pediatric exposure reports for adult formulations primarily through accidental needle-stick events or caregiver errors. These events should be managed as acute toxic exposures with supportive care.

Monitoring Protocols in Pediatric Settings

Cardiology and neonatology guidelines converge on a monitoring framework that should be present before the first drop of IV alprostadil is infused in any neonate. The following parameters are standard at institutions following AHA and AAP recommendations [5]:

Continuous pulse oximetry and cardiorespiratory monitoring must be in place before infusion starts. Arterial access (umbilical arterial catheter or peripheral arterial line) allows real-time blood pressure measurement and serial blood gas sampling. Baseline arterial blood gas establishes pre-treatment oxygen status and guides response assessment. Echocardiography, either formal or point-of-care, should confirm ductal patency and the suspected anatomical diagnosis when feasible.

Temperature is recorded at minimum every four hours given the fever incidence. Any neonate who develops apnea should have the infusion rate halved immediately, with respiratory support initiated per resuscitation protocol. If apnea recurs at the reduced dose, the clinical team must weigh the cardiac benefit of continued patency against the respiratory risk, a decision that belongs exclusively with a pediatric cardiologist and intensivist.

For infusions expected to exceed 14 days, weekly long-bone radiographs and serial measurements of serum alkaline phosphatase are reasonable institutional protocols for detecting cortical hyperostosis early [6].

Congenital Heart Disease: The Core Pediatric Indication

The evidence base supporting IV alprostadil in ductus-dependent congenital heart disease dates to the 1970s, when Olley, Coceani, and Bodach first described PGE1-mediated ductal relaxation in animal models. Subsequent clinical series established that prostaglandin E1 infusion could maintain ductal patency long enough to allow neonates to survive to definitive surgery.

A 2002 systematic review in the Archives of Disease in Childhood pooled data across centers and confirmed that PGE1 successfully maintained ductal patency in over 90% of neonates with ductus-dependent lesions when initiated promptly after birth [7]. The same review found that infusion initiated within the first 24 hours of life was associated with significantly better pre-operative oxygenation (mean PO2 improvement of 26 mmHg) compared to delayed initiation.

The American Heart Association's 2022 guidelines on management of neonates with suspected congenital heart disease state: "Prostaglandin E1 infusion should be initiated immediately upon recognition of a ductus-dependent lesion, without waiting for echocardiographic confirmation, when clinical suspicion is high and the infant is deteriorating" [5]. This guidance reflects decades of evidence that the risk of delayed treatment outweighs the risk of treating an infant who turns out not to have a ductus-dependent lesion.

Specific diagnoses where IV alprostadil is most commonly used include: transposition of the great arteries (where ductal patency supports mixing of oxygenated and deoxygenated blood), pulmonary atresia with intact ventricular septum (where pulmonary blood flow depends on the ductus), critical pulmonary stenosis, hypoplastic left heart syndrome (where systemic perfusion depends on right-to-left ductal flow), and critical coarctation or interrupted aortic arch (where lower body perfusion is ductus-dependent) [4].

In all of these scenarios, alprostadil is a bridge, not a cure. The drug buys time. Definitive management is surgical or catheter-based, and the goal is to wean and discontinue alprostadil as soon as the anatomy is addressed.

Off-Label and Investigational Pediatric Uses

Beyond the established cardiac indication, case reports and small series have explored IV or topical alprostadil in pediatric contexts including:

Peripheral vascular insufficiency in neonates. Catheter-induced arterial spasm and thrombosis in neonates have been treated with low-dose IV PGE1, with some centers reporting vessel patency restoration in small case series [8]. This is off-label use without randomized controlled trial support.

Raynaud's phenomenon in children and adolescents. Severe, treatment-refractory Raynaud's affecting pediatric patients with systemic sclerosis has been managed with short-course IV alprostadil infusions at doses of 0.5 to 2 nanograms/kg/min in small cohorts, though evidence is limited to observational data and no pediatric RCT has been published [8].

Wound healing and frostbite. Topical or systemic PGE1 has appeared in case literature for pediatric frostbite, but sample sizes are too small to draw conclusions about safety or efficacy relative to established frostbite protocols.

None of these off-label uses involve Caverject or MUSE. They all use IV or topical formulations of alprostadil distinct from the adult ED products. Clinicians should not extrapolate adult ED dosing forms to any pediatric indication under any circumstances.

What Caregivers and Patients Should Know

Parents of neonates receiving IV alprostadil in a cardiac ICU frequently encounter this drug during one of the most frightening periods of their lives. Clear, accurate communication from the clinical team matters.

The central messages:

Alprostadil is keeping the ductus open so blood can reach the lungs or the body while the team prepares a definitive fix. The drug is standard care for this condition. The two biggest risks to watch for are breathing pauses and fever, and the nursing team monitors continuously for both. The infusion will be stopped as soon as surgery or catheterization addresses the heart anatomy.

For parents who have searched online and found references to Caverject or MUSE (the adult ED products), the clinical team should explain directly that those formulations have no role in the child's care and carry no relevance to the neonatal IV infusion being administered.

Interactions, Contraindications, and Special Populations Within Pediatrics

IV alprostadil has a narrow contraindication list in neonates. Respiratory distress syndrome is listed as a relative contraindication in some references because the vasodilatory effects may worsen ventilation-perfusion mismatch in an infant with surfactant deficiency, though the cardiac benefit typically dominates the clinical calculus in ductus-dependent lesions [4].

Drug interactions in the neonatal setting center on concurrent vasodilators. Neonates receiving milrinone (a phosphodiesterase-3 inhibitor used for cardiac output support) alongside alprostadil may experience additive hypotension because both agents reduce systemic vascular resistance through distinct pathways. Dose adjustments of one or both agents are sometimes required [9].

Alprostadil undergoes rapid pulmonary metabolism; approximately 68% of a single IV dose is metabolized on first pass through the lungs [4]. This makes neonates with reduced pulmonary blood flow (the very population most likely to receive the drug) potentially susceptible to higher systemic alprostadil exposure per administered dose. Clinicians managing neonates with severely reduced pulmonary flow should consider starting at the lower end of the dosing range (0.05 mcg/kg/min) and titrating by clinical response.

Hepatic metabolism handles the remaining alprostadil not cleared by the lungs. Neonates with hepatic dysfunction (uncommon but possible in the setting of low cardiac output) may accumulate the drug. No specific dose adjustment formula exists in the prescribing label, so clinical response and adverse effect monitoring serve as the guide.

Renal clearance of alprostadil metabolites is the primary elimination route. Neonates with renal insufficiency secondary to low perfusion states should be monitored more closely for adverse effect accumulation, though the rapid pulmonary metabolism means that renal impairment alone rarely necessitates substantial dose reduction in the acute phase [4].